STATEN
ISLAND, N.Y., June 15,
2023 /PRNewswire/ -- Acurx Pharmaceuticals
(Nasdaq: ACXP), a clinical stage biopharmaceutical company
developing a new class of antibiotics for difficult-to-treat
bacterial infections, announced today that Company CEO,
David P. Luci, has been invited to
present at the Maxim Group Virtual Healthcare Conference, hosted by
M-Vest, on Tuesday, June 20, 2023 to
Thursday, June 22, 2023 at
9:00 A.M. ET.
This conference will be live on M-Vest. To attend, just sign up
to become an M-Vest member.
Click Here to Reserve your seat
About the Maxim Group LLC Virtual Healthcare
Conference
The exponential growth in knowledge and expertise in science and
medicine continues to drive opportunities in the healthcare space.
These include multiple therapeutic categories and emerging
technologies, which presenting companies at this year's Maxim
Virtual Healthcare Conference are focused on, and for many, that
includes key data-driven events in 2023. Maxim Senior Analysts will
host a wide range of biotechnology and medical device companies in
a series of presentations and interactive discussions with CEOs and
key management. Maxim will also be hosting several topical industry
panels to provide investor insight into industry sectors and
specific company opportunities.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical
company focused on developing new antibiotics for difficult to
treat infections. The Company's approach is to develop antibiotic
candidates that target the DNA polymerase IIIC enzyme and its
R&D pipeline includes early-stage antibiotic product candidates
that target Gram-positive bacteria, including Clostridioides
difficile, methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant
Streptococcus pneumoniae (DRSP). To learn more about Acurx
Pharmaceuticals and its product pipeline please visit
www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
and other statements containing the words "believes,"
"anticipates," "plans," "expects," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
whether ibezapolstat will benefit from the QIDP designation;
whether ibezapolstat will advance through the clinical trial
process on a timely basis; whether the results of the clinical
trials of ibezapolstat will warrant the submission of applications
for marketing approval, and if so, whether ibezapolstat will
receive approval from the FDA or equivalent foreign regulatory
agencies where approval is sought; whether, if ibezapolstat obtains
approval, it will be successfully distributed and marketed; and
other risks and uncertainties described in the Company's annual
report filed with the Securities and Exchange Commission on Form
10-K for the year ended December 31,
2022 and on Form 10-Q for the quarter ended March 31, 2023, and in the Company's subsequent
filings with the Securities and Exchange Commission. Such
forward-looking statements speak only as of the date of this press
release, and Acurx disclaims any intent or obligation to update
these forward-looking statements to reflect events or circumstances
after the date of such statements, except as may be required by
law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President &
CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-participate-in-the-maxim-group-llc-virtual-healthcare-conference-on-tuesday-june-20-2023-to-thursday-june-22-2023-at-9-am-et-301851588.html
SOURCE Acurx Pharmaceuticals, Inc.